Inovio Pharma (NASDAQ: INO) reported Q3 EPS of ($0.39), $0.14 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $2.6 million versus the consensus estimate of $9.36 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.